Clinical Trials Logo
  1. Home
  2. Leptospirosis
  3. NCT03497572

Seroprevalence Study to Evaluate the Persistence of Anti-leptospira Antibody in Subjects Vaccinated With Spirolept® Vaccine — SPT-001  

Leptospirosis Clinical Trial

Official title:
Seroprevalence, Multi-center, Phase IV Cross-sectional Study to Evaluate the Persistence of Anti-leptospira Antibody in Subjects Vaccinated With Spirolept® Vaccine

Clinical Trial Summary

The study aims to assess antibody persistence induced by Spirolept® vaccination in subjects who received at least 4 doses (2 doses two weeks apart and 2 booster doses) and no more than a total of 8 doses (2 doses two weeks apart and 6 booster doses).

Clinical Trial Description

This is a seroprevalence, phase IV, multi -center study to evaluate anti-Leptospira antibody persistence in subjects who have received at least the 2nd booster (4 vaccine doses) and no more than the 6th booster (8 vaccine doses) of Spirolept® vaccine.

The study will be conducted at the Occupational Health Centre of companies employing workers at risk of leptospirosis for their occupational activities. Study participants will be selected from the company Occupational Health Centre database where each employee is registered. All workers are regularly followed-up and their medical and vaccination history recorded. Subjects selection will occur according the number of booster doses received (having received at least the 2nd booster and no more than the 6th booster). After they have signed the informed consent form, subjects will be recruited into the study and if all inclusion and exclusion criteria are met they will be taken a blood sample.

Anti-leptospira IgG antibody will be measured by a validated ELISA. Other assay may be performed to further characterize anti-leptospira antibodies. Data on subject demographics, relevant medical history, vaccination dates, and blood collection will be recorded in an appropriate Case Report Form.

The study does not include any vaccination. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03497572
Study type Observational
Source Imaxio
Contact
Status Completed
Phase
Start date August 25, 2017
Completion date April 12, 2018
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02898519 - Immune Response After Leptospirosis Infection N/A
Recruiting NCT05425524 - Leptospirosis Care Bundle Study N/A
Completed NCT03912506 - Severe Leptospirosis in Non-tropical Areas
Recruiting NCT04288674 - Leptospirosis Registry - LeptoScope
Recruiting NCT05300425 - Seroprevalence of Leptospirosis in Val Müstair, Switzerland
Completed NCT01080989 - The Sero-Prevalence and Genetic Study for the Infectious Diseases and Metabolic Syndrome in Solomon Islands N/A
Recruiting NCT05436756 - Chronic Post-leptospirosis Manifestations in Reunion N/A
Recruiting NCT04882046 - Study of the Incidence of Jarisch-Herxheimer Reaction in Leptospirosis Patients in New Caledonia N/A
Terminated NCT00592566 - Desmopressin and Dexamethasone Adjunctive Treatment for Leptospirosis Phase 2/Phase 3
Recruiting NCT04034550 - Cohort of Hospitalized Patients Suspected of Leptospirosis N/A
Completed NCT05413720 - Study of the Innate Immune Response to the Acute Phase of Human Leptospirosis - IMMUNOLEPTO N/A
Completed NCT01766830 - Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) N/A
Recruiting NCT02000635 - Study of Decreasing Kinetics of the Leptospiremia During Antibiotic Treatment of Leptospirosis in Martinique
Active, not recruiting NCT01607047 - French West Indies Leptospirosis Study